Trending Now
Shorts

1:18
The Potential Effect of Daraxonrasib for Pancreatic Cancer Management
an hour ago
by
Shubham Pant, MD, MBBS

1:31
Examining a Novel Vaccine in Pancreatic Cancer
a day ago
by
Elizabeth Jaffee, MD

1:52
Discussing the Biggest Unmet Needs to be Addressed at 2026 BTG Lung
a day ago
by
Caroline Seymour(+1 more)

2:02
ATLG vs PTCy as GVHD Prophylaxis in Hematologic Malignancies
2 days ago
by
Johannes Schetelig, MD, MSc

1:03
Outlining the Rationale for an ASCENT-07 Subgroup Analysis in Breast Cancer
3 days ago
by
Yeon Hee Park, MD

1:02
Spotlighting the FDA Approval of Palbociclib Plus Trastuzumab for HER2+ Breast Cancer
3 days ago
by
Shimoli Barot, MD

1:16
Exploring the Potential Role of Cancer Vaccines in Pancreatic Cancer
3 days ago
by
Elizabeth Jaffee, MD

1:35
Breaking Down Zanubrutinib Plus Sonrotoclax in MCL and Next Steps for the Combination
6 days ago
by
Marc S. Hoffmann, MD

0:22
Explaining the Significance of the FDA Approval of Pembro Plus EV in MIBC
6 days ago
by
Matthew D. Galsky, MD

0:42
Targeting PRAME in Melanoma
7 days ago
by
Diwakar Davar, MD
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
3
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
4
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
5

























